◆ 会议时间：2023年2月22-25日
◆ 会议地点：美国 圣莫尼卡

◆ 会议简介：

2023年IASLC肺癌靶向治疗会议将于2023年2月22-25日在美国圣莫尼卡举行，会议由国际肺癌研究协会（IASLC）主办。会议将提供正在进行的有关肺癌最新疗法的临床试验信息，将总结新疗法相关靶点的数据，并分享针对这些靶点的每种药物的临床前和早期临床数据。

国际肺癌研究协会（IASLC）成立于1974年，是全球唯一致力于肺癌研究的组织，由致力于肺癌领域研究的专家们发起和创立,成员包括来自于全球100多个国家的5000多名肺癌专家。IASLC在肺癌和其他胸部恶性肿瘤的病因学、流行病学、预防、诊断、治疗以及与之相关的宣领域开展深入研究，为医学团体与大众服务。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）。

IASLC 2023 Targeted Therapies of Lung Cancer Meeting
Date: February 22 – 25, 2023
Venue: Fairmont Miramar Hotel & Bungalows, Santa Monica, CA, USA

The IASLC Targeted Therapies of Lung Cancer meeting is a dynamic meeting with a long tradition. Meeting presenters will summarize the data on relevant targets for new therapies and share data on preclinical and early clinical data for each of the drugs directed against these targets.

摘要征文投稿：

点此提交摘要>>>Submit Abstract>>>

Only abstract submissions presented by Fellows, Residents & Junior Faculty within two years of appointment and from North America (Canada, USA, Mexico) will be accepted. Proof of fellowship, residence or faculty status (acceptance letter, university ID, letter of employment etc.) will be requested during abstract submission. These restrictions only apply to the lead author/presenter, more senior faculty and pharma company employees may be included as co-authors.

• Research work should be original and innovative. Work can be presented prior to the IASLC 2023 Targeted Therapies of Lung Cancer Meeting but MUST include new information/data.
• Abstract title must not exceed 75 words in length.
• Abstracts must not exceed 500 words in length (not including title and authors).
• Tables may be included, and each will count as 100 words.
• A maximum of two images may be included; each will count as 100 words.
• Tables, images and graphs must be uploaded in GIF, JPEG, JPG or PNG format at 300 dpi and 100% size. Any higher resolution is acceptable.
• Abstracts must be structured with the following headings:
  • Background
  • Methods
  • Results
  • Conclusion
• Please add the above headings (Background, Methods, Results, Conclusion) to each section of your abstract body.
• Abstracts will be accepted in English only
• There is no fee for submitting an abstract
• There is no limit to the number of abstracts you may submit (however an individual may not be offered more than one poster or oral presentation)
• All Abstracts accepted by the Scientific Program Committee will be published in the official meeting program book and on the conference website prior to the meeting and it is mandatory to agree to this at the time of submission

Step 1. Title, Topic and Presentation Type

• The abstract title must not exceed 75 words in length.
• Please select the desired topic for your abstract submission. The scientific program committee reserves the right to move the abstract to another topic should it be seen as a better fit.
• Please note your preferred presentation format. If you would not be comfortable giving an oral presentation, please select Poster Only. NOTE: Selecting Poster/Oral does not guarantee you will be assigned an oral abstract presentation upon acceptance; the final presentation type is determined by the Scientific Program Committee

Step 2. Authors

• Please enter the authors and affiliations of the abstract in title case.
• Only abstract submissions from Junior Faculty (trainees, fellows, PhD students, faculty members in their first two years in an academic position and from North America (Canada, USA, Mexico)) will be accepted. Proof of junior faculty status (acceptance letter, university ID, letter of employment etc.) will be requested during abstract submission. These restrictions only apply to the lead author/presenter, more senior faculty and pharma company employees may be included as co-authors.
• There is no limit to the number of co-authors per abstract
• There is a limit of one presenting author per abstract
• If more than two authors are listed, please select who the presenting author is.
• The presenting author of an accepted abstract must be registered by January 21, 2023
• Should a presenting author not be registered by the deadline the abstract may be removed from the program.

Step 3. Abstract Text

• Do not include Title or Author data in the body of your abstract. Title and author should be entered in the steps above.
• Abstracts may be entered directly into the site or copied and pasted
• Research work should be original and innovative. Work can be presented prior to the IASLC 2023 Targeted Therapies of Lung Cancer Meeting, but MUST include new information/data
• Abstracts must not exceed 500 words in length (not including title and authors)
• Tables may be included, and each will count as 100 words
• A maximum of two images may be included; each will count as 100 words
• Tables, images and graphs must be uploaded in GIF, JPEG, JPG or PNG format at 300 dpi and 100% size. Any higher resolution is acceptable.
• Abstracts must be structured with the following headings:
  • Background
  • Methods
  • Results
  • Conclusion
• Please add the above headings (Background, Methods, Results, Conclusion) to each section of your abstract body. These headings will not count towards your word limit of 500.

Step 4. Preview & Submit

• Please proofread your submission prior to submitting
• Once an abstract is submitted it cannot be deleted, modified or corrected in the system after submission. All submitted abstracts will be published exactly as submitted.
• Any abstracts in “Draft” status after the submission deadline has passed will not be considered for review. It is the abstract submitters responsibility to ensure that all abstracts you wish to be reviewed have been properly submitted.
• Should you need to withdraw a submitted abstract, please contact ttlc2023-program@icsevents.com. Please include the abstract number and abstract title in your email.
• Please carefully review the affiliation of all your co-authors as this is how it will appear in the conference program book as well as on the conference website.
• You will be asked to review and agree to the abstract submission terms & conditions prior to submitting your abstract. Please read the information carefully.

For inquiries, please contact ttlc2023-program@icsevents.com. If your inquiry is regarding a particular draft or submission, please include the abstract number and title in your email.

Dear Colleagues and Friends, 

The IASLC 2023 Targeted Therapies of Lung Cancer Meeting will take place February 22-25, 2023 at the Fairmont Miramar in Santa Monica, California, United States. After two years of virtual meetings, we are thrilled to invite you to join us again in a face-to-face meeting with virtual elements that will enhance participant’s experience and allow anyone from anywhere to join this unique meeting.  

The IASLC Targeted Therapies of Lung Cancer Meeting is a dynamic meeting with a long tradition. Meeting presenters will summarize the data on relevant targets for new therapies and share data on preclinical and early clinical data for each of the drugs directed against these targets. 

We can’t wait to see you again in Santa Monica in February 2023.

注册费：

*Subject to availability 

In-person registration fee includes: 

• Access to all Scientific Sessions, Industry Symposia and Exhibits 
• Poster Viewing and Poster Viewing Reception 
• Welcome Reception and Opening Dinner 
• Networking Breaks and Luncheons 
• Access to Virtual Platform Including Recordings of Sessions (Made Available Within 24 Hours) and Presentation Slides (If Permission Granted by Presenters) 

**Proof of status needs to be provided during the online registration process. Please provide a student card or an official letter on your institution/organization’s letterhead which indicates proof of your status as a Student, Fellow, Trainee, Patient Advocate, Registered Nurse or Allied Health Professional. 

***Developing Nations: List of countries available at www.iaslc.org/Membership/Developing-Countries-List 

Includes: 

• Access to Virtual Platform Including Recordings of Sessions (Made Available Within 24 Hours) and Presentation Slides (If Permission Granted by Presenters) 

◆ 参会对象：
诊断和治疗肺癌患者的医疗保健专业人士，包括临床医生,肿瘤内科医生，科学家，胸外科医生，呼吸科/肺科医师，放射肿瘤学家，放射学家，病理学家,介入放射科医师，基础研究科学家、流行病学家以及高级执业护士和医师助手,以及其他相关专业人士代表。